Open AccessEXPERIENCE WITH THE ROSINSULIN C IN COMBINATION WITH ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN ROUTINE CLINICAL PRACTICE
Author(s) -
О. Д. Рымар,
Алексей Николаевич Иванчихин,
Т.В. Козлова,
Елена Дмитриевна Рузаева,
Юлия Александровна Долинская
Publication year - 2014
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2014-2-61-65
Subject(s) - medicine , metformin , diabetes mellitus , type 2 diabetes , hypoglycemia , insulin , adverse effect , clinical practice , gastroenterology , endocrinology , physical therapy
This study aimed to estimate the efficacy and safety of intermediate-acting insulin Rosinsulin C in patients with type 2 diabetes mellitus inadequately controlled with oral antidiabetic drugs.The present study is a 6-month, prospective, uncontrolled, clinical experience evaluation study using insulin Rosinsulin С for type 2 diabetes patients in daily clinical practice. Episodes of hypoglycaemia, adverse events were recorded. The study included 28 patients with type 2 diabetes, 4 men and 24 women who treated with metformin in combination with sulfonylureas in the highest dose. Indicators of glycosylated hemoglobin (HbA1c) of 8 to 14%, the median HbA1c was 11 (10; 13)% of patients age 65 (57; 72) years, body mass index – 33 (30; 35) kg/m2, waist circumference – 105 (99; 111) cm, diabetes duration – 7 (2; 11) years. With the introduction of Rosinsulin С cartridges carried pen Autopen. At the start of the study and after 3 and 6 months, determined the level of HbA1c, fasting plasma glucose.After 6 months' treatment with Rosinsulin С in combination with oral antidiabetic drugs HbA1c was significantly lowered (–3%) (p = 0,001), fasting plasma glucose level decreased by 5 mmol/L (p = 0,001). There was not severe hypoglycemia during the observation period.This research showed that Rosinsulin C is effective and safe in the treatment of patients with type 2 diabetes who were decompensated with oral antidiabetic drugs and can be recommended for use as the initiation of insulin therapy in routine clinical practice.